SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2004 / Cilt: 38 - Sayı: 3

Efficacy of topical erythromycin, tetracycline and clindamycin in the treatment of acne vulgaris

Akne vulgariste topikal eritromisin, tetrasiklin ve klindamisinin etkinliği

Ali Rıza GÜR
A. Hakan ERBİL
Ercan ARCA
Mustafa PEKER
H. Bülent TAŞTAN
Pages
199–207
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinical improvement was obtained with all drugs (p0.017), tetracycline and clindamycin and erythromycin-clindamycin groups differed from each other with statistical significance (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and design: Topical antibiotics such as erythromycin, tetracycline and clindamycin are widely used and effective on mild and moderate inflammatory forms of acne.
📊
Key Findings & Data:Methods: In this study, we compared the efficacy of topically applied tetracyclin, erythromycin and clindamycin for twelve weeks in randomized sixty cases with mild and moderate acne vulgaris.
💡
Conclusion & Impact:Clinical improvement was obtained with all drugs (p0.017), tetracycline and clindamycin and erythromycin-clindamycin groups differed from each other with statistical significance (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and design: Topical antibiotics such as erythromycin, tetracycline and clindamycin are widely used and effective on mild and moderate inflammatory forms of acne. In this study it was aimed to clarify the efficacy of these drugs and determine if there is a difference between them according to the efficacy. Methods: In this study, we compared the efficacy of topically applied tetracyclin, erythromycin and clindamycin for twelve weeks in randomized sixty cases with mild and moderate acne vulgaris. Sixty cases were divided into three groups and treated with tetracycline, erythromycin and clindamycin. Drugs were applied topically two times a day for twelve weeks. Results: There was no statistically difference of age, duration, acne score, gender and occupation between the groups (p>0.05). Clinical improvement was obtained with all drugs (p0.017), tetracycline and clindamycin and erythromycin-clindamycin groups differed from each other with statistical significance (p

Özet

Topikal antibiyotiklerden eritromisin, tetrasiklin ve klindamisin akne tedavisinde yaygın olarak kullanılmakta olup özellikle hafif ve orta derecede inflamatuar aknede etkilidirler. Çalışmada bu ilaçlar arasında tedavi etkinliği açısından bir fark olup olmadığının araştırılması amaçlandı. Bu karşılaştırmalı çalışmada hafif ve orta derecede akne vulgarisli altmış olguda on iki haftalık topikal tetrasiklin, eritromisin ve klindamisin tedavilerinin etkinlikleri karşılaştırıldı. Çalışmada yirmi olguya tetrasiklin, yirmi olguya eritromisin ve yirmi olguya da klindamisin verildi. İlaçlar on iki hafta süreyle sabah-akşam olmak üzere günde iki kez uygulandı. Gruplar arasında yaş, akne başlama yaşı, akne derecesi, cinsiyet ve meslek yönünden istatistiksel olarak anlamlı fark yoktu (p>0,05). Çalışma sonunda her üç ilaçla da istatistiksel olarak anlamlı düzelme saptandı (p0,017), tetrasiklin-klindamisin ve eritromisin-klindamisin arasındaki fark istatistiksel olarak anlamlı bulundu (p

🔖

Cite This Article

GÜR, A. R., ERBİL, A. H., ARCA, E., PEKER, M., TAŞTAN, H. B. (2022). Efficacy of topical erythromycin, tetracycline and clindamycin in the treatment of acne vulgaris. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 38 - Sayı: 3, 199–207. https://ajindex.com/articles/622236

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cunliffe WJ, Simpson NB: Disorders of the Sebaceous Glands. Textbook of Dermatology, (Eds) Champion RH, Burton JL, Burns DA, Breathnach SM. 6th Edition Vol 3. London, Blackwell Scientific Publications 1998, 1927-1984
  2. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D: Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49(1 Suppl): S1-37
  3. Odom RB, James WD, Berger TG: Acne. Andrew’s Disease of the Skin. Ninth Edition. Philadelphia, WB Saunders Company 2000, 284-296
  4. Savaşkan H, Acar MA, Memişoğlu HR: Yağ bezi hastalıkları. Dermatoloji. (Editörler) Tüzün Y, Kotoğyan A, Aydemir EH, Baransü O. 2nci baskı. İstanbul, Nobel Tıp Kitabevleri 1994, 483-494
  5. Strauss JS, Thiboutot DM: Disease of the sebaceous glands. Dermatology in General Medicine, (Eds) Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith AL, Katz SI, Fitzpatrick TB. 5th Edition Vol 1. New York, Mc Graw Hill Company 1999, 769-784
  6. Chan JJ, Rohr JB: Acne vulgaris: yesterday, today and tomorrow. Australas J Dermatol 2000; 41 Suppl: S69-72
  7. Dreno B, Poli F: Epidemiology of acne. Dermatology 2003; 206(1): 7-10
  8. Aydemir EH: Akne vulgaris etyopatogenez ve histopatolojisi. II. Çukurova Dermatoloji Günleri, (Editörler) Memişoğlu HR, Acar A, Aksungur VL, Özpoyraz M, Denli YG, Uzun S, Karakaş M, Adana, Çukurova Üniversitesi Basımevi 2000, 1-6
  9. Baysal V, Yorgancıgil B, Yıldırım M, Demirci M: Tedaviye dirençli akneli olgularda stafilokok ve propionibakterilerde tetrasiklin direncinin araştırılması. T Klin Dermatoloji 1997; 7:177-80
  10. Turanlı AY, Tarım G: Aknenin sınıflandırılması ve klinik özellikleri. II. Çukurova Dermatoloji Günleri, (Editörler) Memişoğlu HR, Acar A, Aksungur VL, Özpoyraz M, Denli YG, Uzun S, Karakaş M, Adana, Çukurova Üniversitesi Basımevi 2000, 15-17
  11. Karaduman A: Aknede sistemik antibiyotikler ve bakteriyel Direnç. II. Çukurova Dermatoloji Günleri, (Editörler) Memişoğlu HR, Acar A, Aksungur VL, Özpoyraz M, Denli YG, Uzun S, Karakaş M, Adana, Çukurova Üniversitesi Basımevi 2000, 37-43
  12. Leyden J: Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction. Cutis 2001; 67(2 Suppl): 5-7
  13. Zouboulis CC, Piquero-Martin J: Update and future of systemic acne treatment. Dermatology 2003; 206(1): 37-53. 14.